| My Account | Subscribe | Contact Us | Donate |
Home
- Kris Freeman Skis for Olympic Gold
- Good Insulin Injection Practices
- Etiquette for People without Diabetes
- Diabetes Technology and Intimacy
- An American in the UK: Healthcare for Type 1s
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Insulin Articles
Companies Try to Leave Each Other in Inhalable Insulin Dust
Dec 1, 1998
Two more contenders have stepped into the ring in the fight for inhalable insulin. Eli Lilly and Company and Dura Pharmaceuticals, a supplier for respiratory conditions, are financially uniting efforts to achieve inhalable insulin. Using an undisclosed sum from Lilly, Dura will try to suit its technology for a dry powder inhaler (DPI) for use with insulin.
Dura spokesperson Greg Mann emphasized that this announcement represents only a collaboration, and the companies "have not disclosed any information pertaining to development stages."
When Dura began developing the DPI, the idea was that people with asthma could use it as an inhaler. The DPI has several advantages over current inhalers: it contains no CFCs (chlorofluorocarbons); no powdered medication gets trapped in the mouth, as a motor blows it efficiently into the lungs; and people with trouble breathing can still get a full dose, because the motor does the inhaling for them.
After getting the FDA to approve its DPI, Dura's next job is to figure out how to get insulin into a powder form. Eventually, once the technology is ready, Lilly will conduct clinical trials.
Two other companies are already conducting clinical trials as part of the FDA approval process. Inhale Therapeutic Systems of San Carlos, California, in cooperation with Pfizer, has built a device that uses air compression to push powdered insulin into the lungs. Aradigm Corp. of Hayward, California, in conjunction with Novo Nordisk Pharmaceuticals, is developing a battery-operated system that works with liquid aerosol insulin.
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
Dec 1, 1998 - Not Yet Rated
Email to a Friend
Send a link to this page to your friends and colleagues.